0000950170-23-008812.txt : 20230418 0000950170-23-008812.hdr.sgml : 20230418 20230320191747 ACCESSION NUMBER: 0000950170-23-008812 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apexigen, Inc. CENTRAL INDEX KEY: 0001814140 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851260244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 900 INDUSTRIAL ROAD, SUITE C CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650.931.6236 MAIL ADDRESS: STREET 1: 900 INDUSTRIAL ROAD, SUITE C CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Brookline Capital Acquisition Corp. DATE OF NAME CHANGE: 20200603 CORRESP 1 filename1.htm CORRESP

 

 

March 20, 2023

 

 

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance,

100 F Street, N.E.

Washington, D.C. 20549-3628

 

Attention:

 

Josh Gorsky and Joe McCann

 

 

 

Re:

 

Apexigen, Inc.
Registration Statement on Form S-1

File No. 333-269912

Acceleration Request

 

Requested Date: March 21, 2023

Requested Time: 4:05 p.m. Eastern Time,

or as soon thereafter as practicable

 

 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Apexigen, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-269912) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Lance Brady at (650) 565-3836.

Please direct any questions or comments regarding this acceleration request to Lance Brady at (650) 565-3836.

 

[Signature page follows]

 

 

 

 

 

 

 

Sincerely,

Apexigen, Inc.

 

/s/ Xiaodong Yang

Xiaodong Yang, M.D., Ph.D.

Chief Executive Officer

 

 

 

cc:

Francis Sarena, Apexigen, Inc.

Michael E. Coke, Wilson Sonsini Goodrich & Rosati, Professional Corporation

Lance Brady, Wilson Sonsini Goodrich & Rosati, Professional Corporation